Immatics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immatics and other ETFs, options, and stocks.

About IMTX

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics.

CEO

Harpreet Singh-Jasuja

CEOHarpreet Singh-Jasuja

Employees

423

Employees423

Headquarters

Tuebingen, Baden Wuerttemberg

HeadquartersTuebingen, Baden Wuerttemberg

Founded

2020

Founded2020

Employees

423

Employees423

IMTX Key Statistics

Market cap

657.59M

Market cap657.59M

Price-Earnings ratio

-23.56

Price-Earnings ratio-23.56

Dividend yield

—

Dividend yield—

Average volume

636.72K

Average volume636.72K

High today

$5.61

High today$5.61

Low today

$5.18

Low today$5.18

Open price

$5.42

Open price$5.42

Volume

581.77K

Volume581.77K

52 Week high

$13.77

52 Week high$13.77

52 Week low

$3.30

52 Week low$3.30

Analyst ratings

100%

of 8 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own IMTX. This list is generated using Robinhood data, and it’s not a recommendation.

Immatics

Why Robinhood?

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. Show more

IMTX Key Statistics

Analyst ratings

100%

People also own

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics.